A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

Also called NCT02053272

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 207 participants (enrolled count) (from the registry)
Sponsor
Jazz Pharmaceuticals (from the registry)
Registry
  • NCT NCT02053272
  • EudraCT 2013-001140-61
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Romania, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02053272. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2016-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
GWP42004
Intervention (Drug)
Placebo
Lead sponsor
Jazz Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02053272
Content hash
12594584e5526d6534f70e53a36d95fc323a701e5dcfa22d39469b916556b32d